A handful of Big Cap 20 stocks are hovering near buy points. Regeneron Pharmaceuticals (REGN) is trying to clear a 486.10 buy point of a cup-with-handle base. The pattern is late-stage, which makes it risky. Profit and revenue growth have picked up for two straight quarters, with earnings in the latest quarter climbing 27% on a 39% jump in sales. Eylea, a treatment for macular degeneration, is driving the company’s growth.